

# First Embryonic Stem-Cell Trial Gets Approval From the FDA

By RON WINSLOW  
AND ALICIA MUNDY

In a watershed moment for one of the most contentious areas of science and American politics, the U.S. Food and Drug Administration cleared the way for the first-ever human trial of a medical treatment derived from embryonic stem cells.

Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. The announcement caps more than

a decade of advances in the company's labs and comes on the cusp of a widely expected shift in U.S. policy toward support of embryonic stem-cell research after years of official opposition.

"This is the dawn of a new era in medical therapeutics," said Thomas B. Okarma, Geron's president and chief executive officer. The hope that stem-cell therapy will repair and regenerate diseased organs and tissue "goes beyond what pills and scalpels can ever do."

Limits on stem-cell research, which prevented federal funding and were imposed by Congress and former President George W. Bush for ethical and religious reasons, have had a chilling effect on both academic and corporate research involving such cells. Proponents of stem-cell research say restrictions have delayed development of promising new treatments, while critics contend that harvesting stem cells from embryos destroys human life.

President Barack Obama said during his campaign that overturning research limits would be a top priority in his administration.

Both Geron and the FDA said the timing of the decision to approve the study was coincidental. "The FDA looks to the science on these types of issues, and we approve [such applications] based on a showing of safety," said Karen Riley, an FDA spokeswoman. "Political considerations have no role in this process."

Approval of the study is far from a guarantee that stem-cell treatments will work or make it to the market, but it is likely to be seen as an indication that opportunities for stem-cell research are poised to open and will fuel

## The Body Shop

Geron Corp. is developing potential treatments from embryonic stem cells. Some of the cell types (in bold) and the treatments derived from them:

Not shown:  
**Dendritic (immune system):** Cancer

**Cardiac muscle:**  
Heart failure  
heart attack

**Hepatocyte (liver):**  
Liver failure

**Cartilage:**  
Arthritis

**Neural:**  
Spinal cord and other degenerative nervous system diseases

**Osteoblast (bone):**  
Osteoporosis,  
bone fractures

**Islet (pancreas):**  
Diabetes

Source: Geron

enthusiasm among academic and corporate researchers.

Mr. Obama's plans for acting on the current research restrictions haven't been finalized. Shortly after the election, Obama advisers thrilled biotech companies and investors when they suggested that the new president could use his executive authority to undo the Bush administration ban. But in a Jan. 18 interview on CNN, Mr. Obama said he might let Congress take the lead. "I like the idea of the American people's representatives expressing their views on an issue like this," he said.

Regulating stem-cell therapy is new turf for both industry and the FDA, a major reason why it took the agency nearly a year to review Geron's 21,000-page application for the trial, which it filed last March. Approval came in a phone call Wednesday afternoon, Dr. Okarma said.

The study will focus on the safety of the treatment. One concern about stem-cell therapies is whether they will cause cells to grow in places where they aren't wanted. Dr. Okarma said the company's animal research for the spinal-cord treatment hasn't turned up any evidence of such a problem.

At an FDA hearing in April, several firms' executives and researchers complained that they were at a loss about what the FDA wanted in terms of clinical trials involving stem cells because the FDA itself wasn't sure.

Embryonic stem cells are the building-block cells that help drive prenatal development. Geron has developed banks of embryonic stem cells and found a way to coax them into differentiating as they do in nature into

progenitors of specific cells that make spinal-cord tissue, heart muscle, cartilage and other organs and tissues.

Spinal-cord injury is one of medicine's most debilitating conditions, typically causing paralysis and other issues for which there are few, if any, effective treatments. The Geron study will enroll paralyzed patients who can be treated within 14 days of their injury. They will be given a one-time injection of so-called glial cells that the company thinks will essentially restore nerve cells and protective myelin sheaths that are lost in spinal-cord injury.

The company has lined up seven centers to conduct the research. Their names will be disclosed when they are ready to enroll patients. Patients will be evaluated for at least one year, after which, if the treatment proves safe, the company hopes to increase the dose and expand the potential candidates for the therapy.

In addition to safety, researchers will look for signs that the treatment is effective. "If we see safety in this first trial and some response, it will open the flood gates for other investigators, scientists and companies to move broadly into the field of embryonic stem-cell therapy," Dr. Okarma predicted.

Even if the trial succeeds, it is likely to be years before such remedies are approved and widely available to patients.

Rep. Anna Eshoo, a California Democrat in whose district Geron is based, called the development "profound," adding that she looks "forward to Congress approving the kind of research that could lead to medical breakthroughs for the nation."